Targeting apoptosis pathways in pancreatic cancer

Area of Science:

• Oncology
• Molecular Biology
• Cancer Therapeutics

Background:

• Pancreatic ductal adenocarcinoma (PDAC) is a highly therapy-refractory cancer.
• PDAC cells evade apoptosis via molecular alterations in key signaling pathways (e.g., EGFR, PI3K/Akt, NF-κB) and epigenetic modifications.
• Overexpression of apoptosis regulators (e.g., Bcl2, survivin) and histone deacetylases (HDACs) contributes to chemoresistance.

Purpose of the Study:

• To review the molecular mechanisms underlying therapy resistance in PDAC, focusing on anti-apoptotic pathways.
• To explore the potential of novel therapeutic strategies, including combination therapies, for PDAC treatment.
• To highlight the need for new molecular targets and innovative treatment concepts in clinical trials.

Main Methods:

• Review of molecular alterations in PDAC cells related to apoptosis evasion.
• Analysis of signaling pathways involved in resistance, including EGFR/MAPK, PI3K/Akt, and IKK/NF-κB.
• Examination of epigenetic modifications, such as HDAC overexpression, contributing to chemoresistance.

Main Results:

• PDAC cells exhibit significant resistance to apoptotic stimuli like death ligands and chemotherapy drugs.
• Multiple anti-apoptotic pathways and epigenetic regulators are dysregulated in PDAC.
• Preclinical and early clinical studies of targeted inhibitors (proteasome, HDAC, EGFR, Akt, mTOR) have shown limited success.

Conclusions:

• Targeting the multitude of anti-apoptotic pathways in PDAC presents a significant therapeutic challenge.
• Novel combination therapies and new molecular targets are essential for advancing PDAC treatment.
• Further clinical trials are needed to evaluate innovative treatment concepts in neoadjuvant, adjuvant, or palliative settings.